TRDA241220P25000
- 0.00
- 0.000.00%
Entrada Therapeutics Newsroom
Entrada Therapeutics Insider Sold Shares Worth $339,281, According to a Recent SEC Filing
Beyond The Numbers: 4 Analysts Discuss Entrada Therapeutics Stock
Oppenheimer Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $28
Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating
Entrada Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Entrada Therapeutics Analyst Ratings
H.C. Wainwright Maintains Entrada Therapeutics(TRDA.US) With Buy Rating, Raises Target Price to $20
Entrada Therapeutics: Strong Buy Recommendation Backed by Promising Clinical Progress and Robust Financial Health
Express News | Entrada Therapeutics, Inc. : H.c. Wainwright Raises Target Price to $20 From $18
TD Cowen Maintains Entrada Therapeutics(TRDA.US) With Buy Rating
TD Cowen Sticks to Its Buy Rating for Entrada Therapeutics Inc (TRDA)
Entrada Therapeutics GAAP EPS of -$0.35 Beats by $0.44, Revenue of $19.57M Beats by $7.69M
Entrada Therapeutics, Inc. (TRDA) Reports Q3 Loss, Tops Revenue Estimates
Entrada Therapeutics | 10-Q: Q3 2024 Earnings Report
Entrada Therapeutics | 8-K: Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Express News | Entrada Therapeutics Inc: Cash Runway Expected Into 2027
Entrada Therapeutics 3Q Loss/Shr 35c >TRDA
Entrada Therapeutics Reports Third Quarter 2024 Financial Results
Express News | Entrada Therapeutics, Inc. Q3 Income From Operations USD -21.658 Million
Express News | Entrada Therapeutics, Inc. Q3 Net Income USD -14.032 Million